Iranian researchers produced a new type of antibacterial nanodrug in laboratorial research which reduces the consumption dosage by increasing the antibacterial effect of antibiotics as well as controlled release of drug, Iran Nanotechnology Initiative Council reports.

The nanodrug can be used in the treatment of bacterial infection in patients after carrying out complementary studies and mass production.

Some bacteria have become resistant to antibiotics due to the incorrect consumption of the drugs since the discovery of antibiotics. In addition, antibacterial drugs have some problems, including the difficult transference from cell membrane, low activity inside the cells and toxicity on healthy cells of the body. Therefore, researchers have always sought new methods to optimize treatment process by using antibiotics, and reducing the time of treatment.

The aim of the research was to design a controlled drug release system by using dendrimer nanoparticles - highly branched, star-shaped macromolecules with nanometer-scale dimension - and ceftazidime antibiotic - an antibiotic useful for the treatment of a number of bacterial infections - to cure infections caused by gram negative bacteria such as pseudomonas aeruginosa. Based on the results, a controlled release system of drug with high compatibility can be obtained by loading the drug on nanodendrimers.

In this research, ceftazidime drug, was attached to the nanodendrimer in a direct manner without the need for any intermediate. Studies on the release of ceftazidime from dendrimer nanoparticles showed that the amount of release continually increases. The obtained nanosystem has more attraction on pseudomonas aeruginosa bacterium than on pure ceftazidime.

Results of the research have been published in Scientia Iranica F, vol. 22, issue 3, 2015, pp. 1330-1336.